Monorail
Hope, Rerouted
Exvade is developing the Tumor Monorail, giving doctors a new way to reach and understand brain tumors over time.
A new way to access brain tumors over time.
The Tumor Monorail is designed to guide migrating tumor cells from the tumor toward a more accessible reservoir, where tumor material can be collected and studied throughout treatment.
Guide
Create a pathway to the tumor
The implanted nanofiber scaffold is designed to guide tumor cells toward an accessible reservoir.
Collect
Repeat collection without repeat surgery
An accessible reservoir is designed to allow repeated sampling of tumor-derived material during treatment.
Understand
Gain insights to inform treatment
Serial samples could reveal how tumors evolve and respond to therapy, helping inform more personalized treatments.
Exvade, the opposite of ‘invade’, is focused on precision tumor removal
True to its name, Exvade turns cancer’s most dangerous trait into an opportunity for better care. Using bio-inspired cues, our device reroutes the invasive nature of malignant tumors into a safe, controlled pathway.
For the first time, migrating tumor cells can be guided to a small, accessible reservoir where they can be safely removed and analyzed to guide real-time, proactive treatment decisions.
Exvade provides
Real-time access to living tumor tissue in an outpatient setting, overcoming the risks and limitations of traditional biopsies.
Sufficient tumor material for deep insights, including multi-omics analysis to guide precision treatment.
A direct path through the blood-brain barrier, enabling targeted drug delivery once thought impossible.
Enroll in the trial
Exvade is conducting a First-in-Human study of the Tumor Monorail Device at the Preston Robert Tisch Brain Tumor Center at Duke University, evaluating its safety and advancing a transformative shift in how cancer is treated.
Enroll in our clinical trial and contribute to the development of innovative solutions that prioritize patient care and outcomes.
“By allowing real-time monitoring of the tumor over time, while on therapy, we will hopefully be able to more swiftly identify the degree of efficacy or the limitations of our therapies, while preventing the trauma and costs of repeated brain surgery.”
- Dr. Annick Desjardins, MD, FRCPC, neuro-oncologist,
professor of neurosurgery and neurology at Duke University
News
A device that aims to draw aggressive brain tumor cells to the exterior of the brain...
Join the future of cancer treatment
Exvade provides a credible, game-changing opportunity. Backed by high-impact publications, an extensive patent portfolio, and strategic partnerships, we’re building the future of cancer care.
Please feel free to contact us if you are:
A patient or caregiver looking for information about our clinical trial
A biotech company developing new therapies for GBM and interested in collaborating
A pharmaceutical company conducting Phase 1 or 2 clinical studies and interested in accessing tissue during trials
We also welcome inquiries from anyone interested in learning more or exploring other ways to work together.
